Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study.

ABSTRACT:

Background

There is strong rationale for interference with T cell co-stimulation in IgG4-related disease (IgG4-RD), but the literature to evaluate this is limited to a single case report.

Methods

We conducted a ten-subject proof-of-concept trial of abatacept in active IgG4-RD. All subjects met the ACR/EULAR Classification Criteria for IgG4-RD. Subjects received subcutaneous abatacept 125 mg weekly for 24 weeks. Concurrent glucocorticoid treatment was permitted but if used had to be discontinued by week four. The primary endpoint, complete remission at 24 weeks, was defined as an IgG4-RD Responder Index score of 0. Peripheral blood mononuclear cells were collected at baseline, four weeks, and 12 weeks. B and T cell subsets were quantified using a 25-parameter flow cytometry p

SUBMITTER: Matza MA 

PROVIDER: S-EPMC9004478 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature